ESR1 and breast cancer: Similarly, Beclin1 inhibition enhanced paclitaxel-mediated cytotoxicity in BT-474 ER+ breast cancer cells in vitro and contributed to decreased tumor volume in a xenograft model [171], suggesting that Beclin1 protects these cells from drug-induced apoptosis.